Published in Blood Weekly, July 17th, 2003
"Arsenic trioxide (AS2 O3 ) is an effective treatment for acute promyelocytic leukemia (APL), but is less effective against other leukemias. Although the response of APL cells to AS2 O3 has been linked to degradation of the PML/RARalpha fusion oncoprotein, there is evidence that PML/RARalpha expression is not the only mediator of arsenic sensitivity," scientists in Canada report.
"Indeed, we found that exogenous expression of PML/RARalpha did not sensitize a non-APL leukemic line to AS2 O3 . To evaluate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.